CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 29, 2008
Result type: Reports
Project Number: SR0146-000
Product Line: Reimbursement Review

Generic Name: Infliximab

Brand Name: Remicade

Manufacturer: Centocor Inc.

Therapeutic Area: Ulcerative Colitis

Indications: Ulcerative Colitis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 22, 2009

Recommendation Type: Do not list